|
|
Post by hellodolly on Mar 1, 2024 15:59:28 GMT -5
Not heard and missed this, might have been on the last EC. MNKD presenting any new unpublished or non-public data at this conference for the first time? Abstracts, etc not available until March 6.
|
|
|
|
Post by prcgorman2 on Mar 1, 2024 16:08:54 GMT -5
YES!! I think they said they're planning a read-out on the INHALE-1 (pump/switch) trial.
|
|
|
|
Post by centralcoastinvestor on Mar 1, 2024 17:56:31 GMT -5
YES!! I think they said they're planning a read-out on the INHALE-1 (pump/switch) trial. I think you mean Inhale 3. Inhale 1 is the Peds trial. |
|
|
|
Post by sla55 on Mar 1, 2024 18:10:04 GMT -5
YES!! I think they said they're planning a read-out on the INHALE-1 (pump/switch) trial. I think you mean Inhale 3. Inhale 1 is the Peds trial. Afrezza INHALE-3 (T1DM, Afrezza vs. standard of care including AID pumps; phase 4 clinical trial) Enrollment completed ahead of schedule in 4Q 2023 Upcoming expected data read-outs: First meal dosing – ATTD oral presentation in March 2024 17-week top-line data/primary endpoints to be presented at ADA in June 2024 Additional data to be presented at ADCES August conference |
|
|
|
Post by ktim on Mar 1, 2024 18:31:20 GMT -5
Does anyone have any idea what "First meal dosing" presentation might entail? Is the data read-out on the menu selection choices of all the participants for their first Afrezza meal  Based on something I remember seeing, I think many probably chose flying hamburgers... Afrezza is particularly well suited for those  |
|
|
|
Post by daisyz on Mar 1, 2024 18:41:05 GMT -5
Does anyone have any idea what "First meal dosing" presentation might entail? Is the data read-out on the menu selection choices of all the participants for their first Afrezza meal Based on something I remember seeing, I think many probably chose flying hamburgers... Afrezza is particularly well suited for those From clinicaltrials.gov Post prandial glucose for first meal challenge [Time Frame: 17 weeks] Post prandial glucose for first meal challenge |
|
|
|
Post by sayhey24 on Mar 1, 2024 21:53:22 GMT -5
Does anyone have any idea what "First meal dosing" presentation might entail? Is the data read-out on the menu selection choices of all the participants for their first Afrezza meal Based on something I remember seeing, I think many probably chose flying hamburgers... Afrezza is particularly well suited for those Basically - double whats on the label. The label is wrong. Ginger V. has a recent video where she talks about how she doses afrezza including follow-up dosing. |
|
|
|
Post by prcgorman2 on Mar 2, 2024 8:55:50 GMT -5
YES!! I think they said they're planning a read-out on the INHALE-1 (pump/switch) trial. I think you mean Inhale 3. Inhale 1 is the Peds trial. Thank you for the correction! |
|
|
|
Post by sla55 on Mar 6, 2024 12:31:51 GMT -5
bnnbreaking.com/breaking-news/health/mannkind-to-unveil-groundbreaking-inhaled-insulin-study-results-at-attd-conferenceMannKind to Unveil Groundbreaking Inhaled Insulin Study Results at ATTD ConferenceMannKind Corporation announces the INHALE-3 study findings, showcasing the efficacy of inhaled insulin for diabetes, at the ATTD conference in Florence. In a significant stride towards innovation in diabetes care, MannKind Corporation announced the forthcoming presentation of the INHALE-3 study findings at the 17th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) in Florence. This pivotal research evaluates the efficacy of inhaled insulin in comparison to standard treatment methods. Dr. Irl B. Hirsch, a leading figure in diabetes treatment and the study's protocol chair, will spearhead the presentation, spotlighting the trial's initial outcomes, notably from a standardized meal challenge. Revolutionizing Diabetes Management
The INHALE-3 study, a Phase 4 clinical trial conducted in the U.S., investigates the impact of an inhaled insulin regimen alongside basal injections versus conventional care practices. This trial is particularly noteworthy for its use of a higher initial conversion dose for inhaled insulin, a strategy derived from MannKind's preceding ABC study. Preliminary data suggest that this approach significantly reduces post-prandial glucose levels, offering a promising alternative to traditional diabetes management strategies. Dr. Kevin Kaiserman, MannKind's Senior Vice President of Clinical Development and Medical Affairs, emphasizes the trial's potential to reshape our understanding of mealtime insulin control. Insights and ImplicationsSet against the backdrop of Florence's ATTD Conference, Dr. Hirsch's presentation is eagerly anticipated. His discourse will not only cover the comparative efficacy of inhaled insulin but also delve into its broader implications for diabetes care. With the study's larger comparator group and extensive treatment regimen analysis, the INHALE-3 findings could herald a new era in diabetes treatment, emphasizing convenience and efficacy. Further details and subsequent data will be shared after the conference, promising a comprehensive overview of this innovative treatment approach. About MannKind CorporationMannKind Corporation stands at the forefront of therapeutic innovation, dedicated to addressing the unmet medical needs of individuals with endocrine and orphan lung diseases. Leveraging its expertise in dry-powder formulations and inhalation devices, MannKind is committed to improving patient outcomes across a spectrum of conditions, including diabetes, pulmonary arterial hypertension (PAH), and nontuberculous mycobacterial (NTM) lung disease. As MannKind continues to pioneer advancements in healthcare, its dedication to enhancing patient quality of life remains unwavering. As the medical community awaits the detailed findings of the INHALE-3 study, the potential for inhaled insulin to transform diabetes management is palpable. With its commitment to innovation and patient care, MannKind Corporation is poised to redefine treatment paradigms, offering new hope and possibilities for individuals living with diabetes.
|
|
|
|
Post by runner on Mar 6, 2024 14:10:35 GMT -5
Do we know if he is presenting in person in Florence or is it an online presentation?
|
|
|
|
Post by sayhey24 on Mar 6, 2024 15:08:48 GMT -5
Do we know if he is presenting in person in Florence or is it an online presentation? They all went last year. I assumed they all went again. ATTD was where Mike was so amazed by meeting all these "thought leaders". He talked about it on one of the calls. I sure hope he is not doing this virtually. MNKD needs to press the flesh and buy some drinks at the bar. |
|
|
|
Post by prcgorman2 on Mar 6, 2024 15:14:11 GMT -5
Do we know if he is presenting in person in Florence or is it an online presentation? They all went last year. I assumed they all went again. ATTD was where Mike was so amazed by meeting all these "thought leaders". He talked about it on one of the calls. I sure hope he is not doing this virtually. MNKD needs to press the flesh and buy some drinks at the bar. Agree, and who wouldn't want to be in Florence, Italy in March instead of cold damp Seattle? |
|
|
|
Post by hellodolly on Mar 6, 2024 15:15:30 GMT -5
I'm left with the impression these interim results are stellar and therefore, will want to be in the flesh (as sayhey24) alluded to in his reply. "Ground breaking Study" sounds very intense, as well as "a new era in diabetes treatment". Yes, go mono y mono Mike with the KOLs and set the tone for the future of diabetes care. |
|
|
|
Post by runner on Mar 6, 2024 15:39:20 GMT -5
“I sure hope he is not doing this virtually. MNKD needs to press the flesh and buy some drinks at the bar.”
I’m a little concerned that with a presentation at 5:15 pm on a Friday afternoon in Florence, Italy, a lot of attendees will already be in the bar. That’s my experience of conferences, at least.
|
|
|
|
Post by akemp3000 on Mar 6, 2024 16:02:10 GMT -5
If the interim results presented are truly groundbreaking, a variety of scenarios could follow. The most pessimistic perspective would see nothing much happening other than calls for more testing. The most optimistic perspective would see one or more of the big three BPs initiating a move on the company knowing these results could be game changing sooner rather than later. The much more likely scenario falls somewhere in between possibly creating a new important buzz among industry leaders. This presentation seems to have the potential to be an industry milestone with significant attention and follow-up.
|
|
